Directorate Changes

Vectura Group plc

Directorate Changes

Chippenham, UK - 10 June 2016:

Further to the announcements on 16 March 2016 (RNS Number: 2679S) and 8 April 2016 (RNS Number: 7054U), with effect from today's date the Company confirms the following changes to the Board:

· Andrew Oakley has stepped down from the Board; and

· Andrew Derodra, Frank Condella and Thomas Werner have been appointed to the Board as Chief Financial Officer, Vice Chairman and non-executive director respectively.

Andrew Oakley has been an important member of the Company's management team and the Board since he joined in January 2015 and, on behalf of the Company, Chairman Bruno Angelici extends his thanks to Andrew for his service to the business.

Bruno would also like to extend a warm welcome to Andrew Derodra, Frank Condella and Thomas Werner on behalf of the Company, and looks forward to benefiting from their expertise and contribution to the Company's future success.

The information required to be made available under section 430(2B) of the Companies Act 2006 in relation to Andrew Oakley can be found in the Investors section of the Company's website www.vectura.com.

Further to the announcement on 23 March 2016 (RNS Number: 9513S), the Company confirms the following information in respect of Andrew Derodra, Frank Condella and Thomas Werner pursuant to paragraph 9.6.13(1) of the Listing Rules of the UK Listing Authority:

¹ Frank Condella will retire as a director of Juniper Pharmaceuticals Inc. on a date to be confirmed later this year.

No further information is required to be disclosed in respect of Andrew Derodra, Frank Condella or Thomas Werner under paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.